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Introduction
Mifepristone (RU-486) is a synthetic steroid that acts as
a competitive blocker of both progesterone and corti-
sone receptors [1]. Misoprostol is a prostaglandin analog
used to prevent gastric ulcers induced by non-steroidal
anti-inflammatory drugs [2]. The mifepristone/misopro-
stol combination (MMC) is an effective method to ter-
minate early pregnancy [1–3], because mifepristone in-
creases myometrial sensitivity to prostaglandin in preg-
nant women [4]. Taking oral misoprostol 36 to 48 hours
after mifepristone is the most common regimen used
to terminate a pregnancy of up to 49 days [1]. El-Rafaey
et al reported a complete abortion rate of 87% with
this regimen [5], and Peyron et al found a complete
abortion rate of 96% [6]. Our study, which was per-
formed in a community hospital in Taipei, Taiwan, was
designed to determine the complete abortion rate after
administration of MMC.
Materials and Methods
We studied 159 patients who requested legal termina-
tion of pregnancy at Taipei Medical University–Wan Fan
Hospital from October 1, 2001, to November 30, 2002.
We excluded heavy smokers (> 10 cigarettes/day), all
patients with cardiovascular disease, asthma, possible
ectopic pregnancy and hematologic disorders, and pa-
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tients with ultrasonographic proof of pregnancy of
more than 49 days (by measurement of crown-rump
length). Written informed consent was obtained from
each patient before enrollment in the study.
Patients were given 600 mg of oral mifepristone
(Apano; Lotus Pharmaceutical Co Ltd, Taipei, Taiwan)
followed by 600 µg misoprostol 48 hours later. They
were also given four 250 mg tablets of mefenamic acid
and were instructed to use them for relief of abdominal
cramping pain. A 24-hour on-call telephone number
was provided to answer any questions. All patients were
instructed to return for a post-treatment ultrasound
examination on day 14 after taking the first pills.
All patients underwent ultrasonic examination with
real-time ultrasound equipment (Image Point, Hewlett
Packard, Andover, MA, USA), using a 5–10 MHz trans-
ducer to measure endometrial thickness on day 14.
Endometrial thickness was evaluated by vaginal sono-
graphic identification of the long axis (anterioposterior
dimension or height) of the uterus, including both
opposing layers of the endometrium but not the hypo-
echoic halo and intrauterine fluid (Figure) [7]. Patients
who complained of spotting and in whom vaginal
ultrasonography revealed an endometrial thickness of
10 mm or more underwent vacuum aspiration or ther-
apeutic dilatation and curettage (D&C). All removed
specimens were sent for pathology. Patients were con-
sidered to have had an incomplete abortion if the patho-
logic findings revealed trophoblasts or chorionic villae.
Results
We excluded 10 subjects who failed to return for follow-
up on day 14. The remaining 149 subjects had an intra-
uterine pregnancy visible on transvaginal ultrasono-
graphic examination, a mean age of 25.9 years, and
a mean gestational age of 6.2 weeks, as determined
ultrasonographically. Of these women, 26% were nulli-
parous and 74% were multiparous (Table 1).
Of the 149 patients, 108 had successful abortions
without the need for vacuum aspiration or further
treatment (Table 2). The overall efficacy (the rate of
complete abortion without the need for surgery) in this
study population was 72.5% (108/149). Of the 41 wo-
men who required vacuum aspiration or therapeutic
D&C, three had ongoing pregnancies and 38 had spot-
ting and an endometrial thickness of more than 10 mm.
Thus, the incomplete abortion rate, as determined
ultrasonographically, was 27.5% (41/149). Of the 41
women who underwent vacuum aspiration or thera-
peutic D&C, histopathology showed that 32 had re-
tained gestational tissue and nine had decidual tissue.
The pathologically determined incomplete abortion rate
in failed patients was 78% (32/41), and the false-
positive rate was 22% (9/41). Thus, the crude incomplete
abortion rate for those who took MMC was 21.5%
(32/149), and the complete abortion rate was 78.5%.
Figure. Endometrium after mifepristone/misoprostol com-
bination therapy on day 14; the endometrial thickness is about
7.3 mm.
Table 2. Treatment outcomes and result of uterine evacuation
Pregnancies, n 149
Complete abortion without vacuum aspiration or therapeutic D&C, n (%) 108 (72.5)
Vacuum aspiration or therapeutic D&C, n (%) 41 (27.5)
   Ongoing pregnancy 3 (2.0)
   Gestational tissue 29 (19.5)
   Decidual tissue 9 (6.0)
D&C = dilatation and curettage.
Table 1. Demographic characteristics of 149 women
who underwent medical abortion (mean ± standard
deviation)
Age, yr 25.9 ± 4.4
Gestational age, wk 6.2 ± 1.1
Nulliparous women, % 26.2 (39/149)
Multiparous women, % 73.8 (110/149)
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Discussion
MMC is an alternative to vacuum aspiration for termi-
nation of an early pregnancy. The results in our study
were similar to those in previously reported studies [2].
Patients who undergo vacuum aspiration have heavi-
er vaginal bleeding, infection, and mechanical trauma
compared with those who receive MMC [2].
Rulin et al found that when the endometrial stripe is
about 10 mm wide, products of conception are unlikely
to be detected [8]. Other studies have used the crite-
rion of an endometrial stripe of 8 mm or less [9]. In our
study, we used the same criterion as Rulin et al, a bilayer
endometrial stripe of 10 mm.
In France, MMC is highly effective when used to
terminate a pregnancy of up to 49 days of amenorrhea,
with a complete abortion rate of 94% to 96%. The
frequency of an ongoing pregnancy was 0.4% to 0.9%
[10]. In our study, most patients were Taiwanese. Of the
149 cases, 117 (78.5%) had complete abortions. There
were three ongoing pregnancies, giving a frequency of
2%. This discrepancy in findings suggests that the MMC
regimen used for people in France may not be adequate
for all people in Taiwan. However, there are many
studies on this topic and the optimal use of MMC still
needs to be established [11].
Some studies have revealed that oral misoprostol is
less effective in causing abortion and leads to more side
effects than misoprostol given vaginally [3]. Oral
misoprostol is licensed for the prevention of gastric
ulcers induced by non-steroidal anti-inflammatory drugs.
This tablet is cheap, stable, and effective for medical
abortion [2], but it was not developed and manufactured
for use by other than the oral route. We chose to use
600 µg of oral misoprostol in MMC because the vaginal
route is uncomfortable and painful for the patient [12].
More studies on the best MMC regimen for the legal
termination of early pregnancy are needed for different
populations. Furthermore, studies on developing a drug
that can be administered by different routes are still
needed.
In conclusion, previous studies on patient satisfac-
tion with medical abortion revealed two disadvantages:
the need for many office visits and the prolonged time
of waiting until the abortion was over [13,14]. In our
study, vacuum aspiration in women with vaginal bleeding
or spotting and an endometrial thickness of more than
10 mm by transvaginal ultrasonography 2 weeks after
taking MMC can decrease the number of office visits
and increase patient satisfaction with medical abortion.
The complete abortion rate after oral MMC was 78.5%.
References
1. Mahajan DK, London SN. Mifepristone (RU-486): a review.
Fertil Steril 1997;68:967–976.
2. Bygdeman M, Danielsson KG, Marions L, Swahn ML. Preg-
nancy termination. Steroids 2000;65:801–805.
3. Wiebe ER. Misoprostol administration in medical abortion.
A comparison of three regimens. J Reprod Med 2001;46:125–
129.
4. Bygdeman M, Swahn ML. Progesterone receptor blockage:
effect on uterine contractility and early pregnancy. Contracep-
tion 1985;32:45–51.
5. El-Rafaey H, Rajasekar D, Abdalia M, Calder L, Templeton A.
Induction of abortion with mifepristone (RU-486) and oral
or vaginal misoprostol. N Engl J Med 1995;332:983–987.
6. Peyron R, Aubeny E, Targosz V, et al. Early termination of
pregnancy with mifepristone (RU 486) and the orally active
prostaglandin misoprostol. N Engl J Med 1993;328:1509–
1513.
7. Deichert U, Hackeloer BJ, Daume E. The sonographic and
endocrinologic evaluation of the endometrium in the luteal
phase. Hum Reprod 1986;1:219–222.
8. Rulin MC, Bornstein SG, Campbell JD. The reliability of
ultrasonography in the management of spontaneous
abortion, clinically thought to be complete: a prospective
study. Am J Obstet Gynecol 1993;168:12–15.
9. Wong SF, Lam MH, Ho LC. Transvaginal sonography in the
detection of retained products of conception after first
trimester spontaneous abortion. J Clin Ultrasound 2002;30:
428–432.
10. Ulmann A, Silvestre L, Chemama L, Rezvani Y, Renault M,
Aguillaume CJ, Baulieu EE. Medical termination of early
pregnancy with mifepristone (RU-486) followed by a
prostaglandin analogue. Acta Obstet Gynecol Scand 1992;71:
278–283.
11. Tang OS, Xu J, Cheng L, Lee SW, Ho PC. Pilot study on the use
of sublingual misoprostol with mifepristone in termination
of first trimester pregnancy up to 9 weeks’ gestation. Hum
Reprod 2002;17:1738–1740.
12. Ho PC, Ngai SW, Liu KL, Wong GC, Lee SW. Vaginal
misoprostol compared with oral misoprostol in termination
of second trimester pregnancy. Obstet Gynecol 1997;90:735–
738.
13. Winikoff B. Acceptability of medical abortion in early
pregnancy. Fam Plann Perspect 1995;185:142–148.
14. Schaff EA, Stadalius LS, Eisinger HS, Franks P. Vaginal
misoprostol administered at home after mifepristone (RU-
486) for abortion. J Fam Pract 1997;44:353–360.
